Resources for GEN Readers

Genetic modifications permit more telling—and more sparing—use of animal models in basic research and therapeutic development. GEN spoke with five leading small animal model developers to learn more about how they are responding to the market and regulatory forces.

Humanized in vivo and in vitro systems are becoming more clinically relevant and facilitating better decisions earlier in drug development.

Taconic Biosciences suggests that preclinical findings may translate more readily to human patients if researchers use multiple models.

Preclinical study outcomes are more likely to predict clinical study outcomes if new, better-humanized small animal models are deployed.

Focused, low-energy ultrasound helps researchers deliver drugs only to where their effect is desired, without compromising the blood-brain barrier.

In response to drug development challenges, animal models are acquiring more human-like genetic backgrounds, immune systems, and microbiomes

Instead of executing extensive overhauls, genomic mechanics are using CRISPR tools to make only the most targeted—and safest—repairs

You can select a rodent model that adequately captures human biology for your application, says Taconic Biosciences, and you can do so while being practical.